Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06643936 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

E3 Diabetes - Closing the Gap in Diabetes Control

Study acronym: E3Diabetes
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Oct 1, 2026 → Dec 31, 2026
See other at-risk trials from Rush University Medical Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Oct 1, 2026 to Dec 31, 2026
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 1 of 4 entries
  2. Primary and study completion dates: Apr 1, 2026 to Oct 1, 2026v5
  3. Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Primary and study completion dates: Nov 2025 to Apr 1, 2026
    v4
  4. Re-verified, no change to tracked fieldsv3
  5. Start date: Oct 2024 to Nov 18, 2024v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to decrease the racial gap in type 2 diabetes control in African American and Latinx patients in Rush University Medical Center clinics.
Trial Details
NCT Number NCT06643936
Lead Sponsor Rush University Medical Center
Collaborators: Novartis Pharmaceuticals
Conditions
(from sponsor)		 Type 2 Diabetes
Related terms Diabetes Mellitus, Type 2
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov